Plain-English translation of NCT07570654 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
The Redefine Study is testing whether COMP360, a lab-made form of psilocybin, can help reduce post-traumatic stress disorder (PTSD) symptoms. Participants will receive the medication alongside careful monitoring and support from a trained research team. Researchers want to understand if this treatment can offer relief for people who have been living with PTSD.
Current PTSD treatments don't work well for everyone, and many people continue to struggle with symptoms. This trial is exploring whether this medication, given with professional support, might offer a new way to help people recover from trauma.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of three different doses of the medication during study visits where trained staff will monitor your response and provide support. The trial combines both blinded testing (where some participants don't know which dose they're getting) and open-label phases to evaluate both how well the treatment works and how safe it is. Throughout the study, you'll have regular check-ins with the research team to track your symptoms and well-being.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States